Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remdesivir pharmacokinetics and safety in COVID-19 patients with impaired renal function
NL-OMON51092Phase 4Active, not recruiting
- Sponsor
- HagaZiekenhuis
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remdesivir in coronavirus disease 2019 (COVID-19), sponsored by HagaZiekenhuis. Primary endpoints: Remdesivir plasma 24-hour area under the curve, GS-441524 plasma 24-hour area under the curve and 1 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51092.